Aug 13, 2026 08:31AM
Aug 13, 2026 08:30AM
Aug 11, 2026 08:31AM
Aug 11, 2026 08:30AM
Jul 30, 2026 08:30AM
Jul 30, 2026 08:30AM
Jul 2, 2026 08:30AM Cingulate added to Russell 3000E index
Jul 2, 2026 08:30AM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM
Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM
May 14, 2026 08:03AM
May 14, 2026 08:00AM Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Mar 18, 2026 08:00AM
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:01AM Cingulate reports positive phase 3 trial results for ADHD drug CTx-1301
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Aug 19, 2025 08:45AM Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Aug 15, 2025 09:02AM
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM
Jul 9, 2025 08:03AM Cingulate names Nilay Patel as chief legal officer ahead of FDA filing
Jul 9, 2025 08:00AM
May 20, 2025 08:03AM
May 20, 2025 08:00AM
May 14, 2025 08:04AM
May 14, 2025 08:00AM
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM
Jan 7, 2025 07:30AM
Dec 23, 2024 07:30AM Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
Nov 7, 2024 07:30AM

330,739 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All